A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Trial Profile

A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs IMM 124E (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Immuron
  • Most Recent Events

    • 09 Nov 2017 According to an Immuron media release, Last Patient Last Visit has been completed and data due in the first quarter of next year (Q1 CY2018).
    • 18 Oct 2017 Status changed from active, no longer recruiting to completed, according to an Immuron media release.
    • 19 Sep 2017 According to an Immuron media release, this study is being led by Dr. Arun Sanyal and is expected to yield top-line results in the fourth quarter (Q4) of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top